Christopher Ogden - 02 Feb 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTMX
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:23:47 UTC
Prior SEC filing: 30 Sep 2025
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden

Key filing fact

Christopher Ogden filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 04 Feb 2026.

Key facts

This page summarizes Christopher Ogden's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:23.

Change

Previous filing in this sequence was filed on 30 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914523 Primary reporting owner

Ogden Christopher

Relationship: Chief Financial Officer
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTMX transaction

Common Stock

Award

Transaction value: $0
Shares: +90,000
Change %: +40%
Price: $0.000000
Shares after: 316,271
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +325,000
Change %
Price: $0.000000
Shares after: 325,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 325,000
Exercise price: $6.09
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.

Footnote F2

Includes 239,987 RSUs.

Footnote F3

1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.